Home | Welcome to Contract Pharma   
Last Updated Wednesday, May 22 2013
Print

Financial Report: Alexion 3Q



Published October 24, 2012
Alexion

3Q Revenues: $294.1 million (+44%)

3Q Earnings: $92.2 million (+41%)

YTD Revenues: $813.6 million (+46%)

YTD Earnings: $173.9 million (+37%)

Comments: Soliris sales were $294.1 million in the quarter, up 44%. R&D expenses were $54.3 million, compared to $36.6 million in 3Q11. Results were positively impacted by the terms of a patent settlement and license agreement, for which the company recognized a gain of $53.4 million in cost of sales, net of the effect of an upfront payment.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On